KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) EBT (2016 - 2025)

Gilead Sciences' EBT history spans 17 years, with the latest figure at $2.1 billion for Q4 2025.

  • For Q4 2025, EBT fell 4.11% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $9.8 billion, up 1319.86%, while the annual FY2025 figure was $9.8 billion, 1319.71% up from the prior year.
  • EBT reached $2.1 billion in Q4 2025 per GILD's latest filing, down from $3.6 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $3.6 billion in Q3 2025 to a low of -$4.5 billion in Q1 2024.
  • Average EBT over 5 years is $1.6 billion, with a median of $1.9 billion recorded in 2021.
  • Peak YoY movement for EBT: soared 955.26% in 2023, then plummeted 445.08% in 2024.
  • A 5-year view of EBT shows it stood at $759.0 million in 2021, then surged by 167.59% to $2.0 billion in 2022, then dropped by 18.61% to $1.7 billion in 2023, then surged by 31.09% to $2.2 billion in 2024, then fell by 4.11% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's EBT are $2.1 billion (Q4 2025), $3.6 billion (Q3 2025), and $2.4 billion (Q2 2025).